Y.D. More Investments Ltd Sells 60,039 Shares of Kamada Ltd. $KMDA

Y.D. More Investments Ltd lessened its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 18.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 269,665 shares of the biotechnology company’s stock after selling 60,039 shares during the period. Y.D. More Investments Ltd’s holdings in Kamada were worth $1,878,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. ARK Investment Management LLC purchased a new position in shares of Kamada during the 2nd quarter valued at $1,972,000. Jane Street Group LLC bought a new position in Kamada in the 1st quarter worth about $582,000. Goldman Sachs Group Inc. purchased a new stake in shares of Kamada in the 1st quarter valued at about $497,000. Essex Investment Management Co. LLC raised its holdings in shares of Kamada by 22.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after acquiring an additional 72,602 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Kamada during the 2nd quarter valued at about $472,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KMDA. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. HC Wainwright lifted their price objective on shares of Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Benchmark reissued a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Kamada has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Kamada Stock Up 0.5%

Shares of Kamada stock traded up $0.05 on Friday, hitting $8.71. The stock had a trading volume of 2,814 shares, compared to its average volume of 78,279. Kamada Ltd. has a one year low of $5.54 and a one year high of $9.08. The stock’s 50-day simple moving average is $7.86 and its two-hundred day simple moving average is $7.26. The stock has a market cap of $500.68 million, a price-to-earnings ratio of 24.32, a PEG ratio of 0.75 and a beta of 0.94.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.